Targeted therapies: bevacizumab--has it reached its final resting place?

Nat Rev Clin Oncol. 2011 Mar 8;8(4):195-6. doi: 10.1038/nrclinonc.2011.32.
No abstract available

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Clinical Trials as Topic
  • Humans
  • Neoplasms / drug therapy*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab